科拓生物
(300858)
| 流通市值：30.21亿 | | | 总市值：44.48亿 |
| 流通股本：1.79亿 | | | 总股本：2.63亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 273,787,504.09 | 191,596,438.14 | 349,156,135.27 | 129,464,521.89 |
| 应收票据及应收账款 | 44,385,649.28 | 67,668,898.28 | 61,764,431.05 | 57,162,250.29 |
| 其中：应收票据 | 2,891,131.24 | 2,273,418.18 | 1,306,000.52 | 2,554,406.83 |
| 应收账款 | 41,494,518.04 | 65,395,480.1 | 60,458,430.53 | 54,607,843.46 |
| 预付款项 | 9,933,309.41 | 5,716,142.79 | 9,871,638.86 | 10,663,121.76 |
| 其他应收款合计 | 917,602.41 | 887,673.85 | 1,776,973 | 1,686,334.82 |
| 存货 | 35,685,785.06 | 39,222,641.95 | 47,745,665.25 | 47,020,731.31 |
| 一年内到期的非流动资产 | 362,126,774.7 | 483,000,045.72 | - | - |
| 其他流动资产 | 20,159,549.97 | 15,197,020.23 | 510,561,609.58 | 522,105,487.3 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 901,392,887.26 | 955,551,110.53 | 1,104,433,399.67 | 1,148,118,523.07 |
| 非流动资产: | | | | |
| 长期股权投资 | 1,978,534.13 | 2,017,506.1 | 2,072,697.9 | 2,170,835.18 |
| 其他权益工具投资 | 602,041 | 602,041 | 602,041 | 602,041 |
| 固定资产 | 203,700,453.96 | 207,054,970.58 | 209,345,412.28 | 190,684,182.45 |
| 在建工程 | 204,678,081.03 | 156,652,040.89 | 121,378,665.92 | 72,775,401.41 |
| 使用权资产 | 4,458,316.95 | 11,345,664.39 | 11,139,054.17 | 11,513,386.94 |
| 无形资产 | 50,176,401.56 | 51,058,706.41 | 50,516,212.09 | 51,387,327.61 |
| 商誉 | 1,913,334.43 | 1,913,334.43 | 1,913,334.43 | 1,913,334.43 |
| 长期待摊费用 | 2,803,188.99 | 2,978,568.21 | 53,132.56 | 70,843.4 |
| 递延所得税资产 | 6,270,079.19 | 6,167,921.06 | 4,532,662.76 | 4,790,004.92 |
| 其他非流动资产 | 427,348,721.93 | 414,758,937.3 | 276,916,027.94 | 256,997,280.35 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 903,929,153.17 | 854,549,690.37 | 678,469,241.05 | 592,904,637.69 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 1,805,322,040.43 | 1,810,100,800.9 | 1,782,902,640.72 | 1,741,023,160.76 |
| 流动负债: | | | | |
| 应付票据及应付账款 | 15,792,181.05 | 16,060,770.66 | 28,592,008.19 | 15,039,013.08 |
| 应付账款 | 15,792,181.05 | 16,060,770.66 | 28,592,008.19 | 15,039,013.08 |
| 合同负债 | 12,544,445.95 | 17,121,758.03 | 12,710,153.04 | 10,125,340.6 |
| 应付职工薪酬 | 4,608,544.52 | 11,521,020.42 | 4,426,807.86 | 4,177,862.09 |
| 应交税费 | 4,524,904.06 | 7,283,222.67 | 3,336,397.84 | 5,828,392.41 |
| 其他应付款合计 | 2,933,905.27 | 3,480,227.64 | 3,543,864.78 | 2,299,442.28 |
| 一年内到期的非流动负债 | 741,777.86 | 1,749,430.84 | 1,727,191.7 | 1,684,429.01 |
| 其他流动负债 | 847,127.79 | 1,421,407.57 | 1,244,904.52 | 742,987.93 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 41,992,886.5 | 58,637,837.83 | 55,581,327.93 | 39,897,467.4 |
| 非流动负债: | | | | |
| 租赁负债 | 4,004,132.74 | 9,903,944.86 | 9,340,924.36 | 10,078,756.26 |
| 递延收益 | 5,139,122.87 | 5,864,026.06 | 3,320,000 | 4,243,804.19 |
| 递延所得税负债 | 2,668,325.68 | 2,693,864.34 | 3,133,583.46 | 2,601,590.02 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 11,811,581.29 | 18,461,835.26 | 15,794,507.82 | 16,924,150.47 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 53,804,467.79 | 77,099,673.09 | 71,375,835.75 | 56,821,617.87 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 263,495,118 | 263,495,118 | 263,495,118 | 263,495,118 |
| 资本公积 | 1,105,307,155.46 | 1,105,307,155.46 | 1,105,307,155.46 | 1,109,654,882.87 |
| 盈余公积 | 40,351,705.04 | 40,351,705.04 | 39,324,296.46 | 39,324,296.46 |
| 未分配利润 | 342,363,594.14 | 323,847,149.31 | 303,400,235.05 | 271,727,245.56 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 1,751,517,572.64 | 1,733,001,127.81 | 1,711,526,804.97 | 1,684,201,542.89 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 1,751,517,572.64 | 1,733,001,127.81 | 1,711,526,804.97 | 1,684,201,542.89 |
| 负债和股东权益合计 | 1,805,322,040.43 | 1,810,100,800.9 | 1,782,902,640.72 | 1,741,023,160.76 |
| 公告日期 | 2024-04-25 | 2024-04-25 | 2023-10-25 | 2023-08-02 |
| 审计意见(境内) | | 标准无保留意见 | | |